H.C. Wainwright initiated coverage of Achieve Life Sciences (ACHV) with a Buy rating and $12 price target The firm believes the company’s lead asset, cytisinicline oral tablet, has the potential to address a large unmet need in nicotine addiction treatment through a “differentiated” efficacy and tolerability profile.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACHV:
- Achieve Life Sciences’ Earnings Call Highlights Progress and Challenges
- Optimistic Buy Rating for Achieve Life Sciences Driven by Strategic Advances and Financial Strength
- Achieve Life Sciences Advances Cytisinicline Development
- Achieve Life Sciences reports Q2 EPS (37c), consensus (35c)
- ACHV Earnings Report this Week: Is It a Buy, Ahead of Earnings?